News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Latecoere swung to positive 2025 operating cash flow (€10.5m) and narrowed its net loss, expecting higher volumes and EBITDA in 2026.
  • Ukrainian assessment says Russian satellite reconnaissance and cyber cooperation helped Iran target military and infrastructure across the Middle East.
  • Estée Lauder and Puig family representatives will meet in New York to negotiate governance, shareholder terms and an exchange ratio for a possible merger.
  • Asian FX markets stalled as traders awaited a U.S. deadline on Iran and upcoming RBA and U.S. inflation data.
  • Australian shares rose as the S&P/ASX 200 gained 1.74%, led by tech, metals and materials.
  • Pershing Square submitted a non-binding €30.40-per-share offer for Universal Music Group, proposing cash-and-stock consideration and a 17% share cancellation plan.
  • Goldman cut its 2026 copper forecast to $12,650/tonne, citing weaker demand and increased short-term price vulnerability.

Latest Articles

Carney Rejects Claim He Retracted Davos Remarks After Call with Trump

Carney Rejects Claim He Retracted Davos Remarks After Call with Trump

Canadian Prime Minister Mark Carney on Tuesday denied that he had recanted remarks he made at Davos after a reported U.S. reaction. Carney confirmed a phone conversation with U.S. President Donald Trump and directly told reporters he did not walk back his earlier comments, saying he told Trump he "meant what I said in Davos." He also said the call …

Cardiff Oncology Shares Collapse After Phase 2 Onvansertib Update

Cardiff Oncology Shares Collapse After Phase 2 Onvansertib Update

Cardiff Oncology's stock fell almost 30% in premarket trading Tuesday after the company released Phase 2 data for onvansertib combined with standard first-line therapy in RAS-mutated metastatic colorectal cancer. While the 30mg arm produced a notably higher confirmed objective response rate than standard of care and was well-tolerated, the market r…

Truist Upholds Hold on VF Corp as Brand Results Show Mixed Momentum

Truist Upholds Hold on VF Corp as Brand Results Show Mixed Momentum

Truist Securities reaffirmed a Hold rating and an $18.00 price target on VF Corp, noting a recent modest shift in investor sentiment and mixed brand-level trends. The stock is trading above the target at $20.01 after a near 60% six-month rally, while valuation metrics remain elevated. Other brokerages have moved price targets in both directions, re…

Genenta Science to Rebrand and Pivot into Italian Defense Consolidator

Genenta Science to Rebrand and Pivot into Italian Defense Consolidator

Genenta Science SpA ADR said it will change its name to Saentra Forge S.p.A. and redirect its corporate strategy toward acquiring privately held Italian businesses in national security sectors governed by Italian Golden Power rules. The announcement, which included a binding agreement to fund and potentially acquire a controlling stake in ATC - a N…

Sysco Raises Full-Year Profit Outlook as U.S. Demand Strengthens

Sysco Raises Full-Year Profit Outlook as U.S. Demand Strengthens

Sysco lifted its fiscal outlook and exceeded estimates for second-quarter profit and sales after a pickup in U.S. foodservice demand. The company reported positive U.S. local case volume, margin expansion internationally, and said cost controls helped offset input-price pressures, prompting a premarket share gain.

Burry Reopens Position in GameStop, Sees Stock as a Bet on CEO Ryan Cohen Rather Than Another Meme-Fueled Squeeze

Burry Reopens Position in GameStop, Sees Stock as a Bet on CEO Ryan Cohen Rather Than Another Meme-Fueled Squeeze

Investor Michael Burry has revealed a stake in videogame retailer GameStop and published an analysis explaining why he views the company as a wager on CEO Ryan Cohen's ability to deploy cash into a transformative acquisition, rather than a ticket to another explosive short squeeze. Burry, who previously owned GameStop shares in 2018 and sold them s…

UBS Identifies Four European Telecom Stocks to Watch in 2026

UBS Identifies Four European Telecom Stocks to Watch in 2026

UBS strategists, including Polo Tang and Ondrejsek Cabejsek, argue Europe's telecom sector could undergo a valuation reset provided investors are selective on timing and stock choice. After lagging the broader market in 2025, the sector may benefit from capex tailwinds as heavy fibre rollouts wind down. UBS highlights four preferred names — Orange,…

Chile Tests Underwater Wine Cellars Near Island of Locos

Chile Tests Underwater Wine Cellars Near Island of Locos

A Chilean diving operation is submerging wine bottles in metal cages on the sea floor around the small island of Locos to harness the ocean’s stable temperature, pressure and light for wine aging. The initiative, led by Cava Indus 8 and the ODC diving center in the Coquimbo region, places wines 10-20 meters deep for eight months to a year in calcar…

Outset Medical Shares Rise After FDA Clears Upgraded Tablo Dialysis System

Outset Medical Shares Rise After FDA Clears Upgraded Tablo Dialysis System

Outset Medical Inc (NASDAQ:OM) saw its stock jump 9% in premarket trading Tuesday after the company announced that the U.S. Food and Drug Administration cleared its next-generation Tablo hemodialysis platform. The updated system is the first dialysis unit cleared to meet the FDA's most stringent cybersecurity guidance published in June 2025 and inc…

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Securities increased its price target on Nuvation Bio Inc to $13.00 from $11.00 and kept a Buy rating following the company’s fourth-quarter 2025 pre-report and a one-on-one meeting with management. The firm highlighted stronger-than-expected early uptake of Ibtrozi and the drug’s positioning in the ROS1 treatment landscape, while noting pot…